INTRODUCTION
Patients with acute myocardial infarction (AMI), comprising ST-segment elevation myocardial infarction (STEMI) and non-STEMI (NSTEMI), are often treated with percutaneous coronary intervention (PCI). Clinical trials have confirmed the efficacy of PCI in the treatment of AMI. [1] [2] [3] Furthermore, use of stents has been shown to reduce major adverse cardiac events (MACE) compared with balloon angioplasty alone. 4 However, the choice of stent in patients undergoing PCI for AMI remains debatable as AMI is a risk factor for device-related adverse outcomes, including stent thrombosis. 5 Bare metal stents (BMS) minimise the risk of acute closure and constrictive remodelling compared with balloon angioplasty, but are associated with restenosis due to neointimal hyperplasia. First-generation drug-eluting stents (DES) releasing sirolimus or paclitaxel from durable polymers reduce the need for repeat revascularisation, but delay vessel healing due to chronic inflammation induced by the presence of durable polymer. Meta-analyses have shown no significant difference in mortality, myocardial infarction (MI) and stent thrombosis at 1 year between BMS and first-generation DES, but have shown a significant reduction in target vessel revascularisation in the DES group. 6 7 Conversely, clinical studies and meta-analyses have also raised concerns about late and very late stent thrombosis with use of DES in AMI. [8] [9] [10] [11] Newer-generation DES with biocompatible or biodegradable polymers have been shown to have better safety and efficacy. 12 13 In particular, DES with biodegradable polymers provide controlled drug release with subsequent degradation of the polymer rendering the stent surface more close to a BMS after the period of biodegradation. A few studies have compared the newer-generation DES against firstgeneration DES and reported conflicting outcomes at 1-3 years' follow-up. 14 15 Due to concerns about very late stent thrombosis, further follow-up data are warranted; however, to date, there are no longerterm (5-year) follow-up data for comparison of the newer-generation DES against first-generation DES in patients with AMI. Thus, we hypothesised that coronary intervention with a biodegradable polymer biolimus-eluting stent (BES) would improve clinical outcomes compared with intervention with a durable polymer sirolimus-eluting stent (SES) in AMI subpopulation of the 'all-comers' Limus Eluted from A Durable versus ERodable Stent (LEADERS) coating trial. 
METHODS
The LEADERS trial was conducted in accordance with the principles of the Declaration of Helsinki, and all site-specific Institutional Review Boards and applicable regulatory agencies approved the study protocol before study initiation.
LEADERS trial
Study design of the LEADERS trial (NCT 00389220) has been previously described 16 17 and is outlined in figure 1 . Briefly, this was an all-comers prospective, multicentre, randomised, assessorblind, non-inferiority trial. Patients (n=1707) with age >18 years and symptomatic coronary artery disease with >50% stenosis in one or more native coronary arteries or saphenous vein bypass graft were included. Exclusion criteria were limited and included pregnancy, known intolerance to aspirin, clopidogrel, heparin, stainless steel, sirolimus, biolimus and contrast material, inability to provide informed consent, patient participation in another trial before reaching the primary endpoint or planned surgery within 6 months of PCI unless dual antiplatelet therapy was maintained throughout the perioperative period. Patients were 1:1 randomised to either BES (BioMatrix Flex, Biosensors Europe, Morges, Switzerland) or SES (Cypher Select, Cordis Corporation, Bridgewater, New Jersey, USA).
The current study included all patients with AMI (including STEMI and NSTEMI) in the LEADERS cohort. As an 'allcomers' trial, no limitation was placed on the number of treated lesions, number of vessels or lesion length according to the randomisation group. Patients were mandated to receive the same stent type for all lesions. All procedures were performed according to routine local clinical practice using standard techniques.
Study endpoints
The primary endpoint of the LEADERS trial was MACE, defined as composite of cardiac death, MI (Q-wave and non-Q-wave) or clinically indicated target vessel revascularisation within 9 months. For this substudy, we report MACE at 5 years and patient-oriented composite endpoint (POCE), a more comprehensive endpoint including all-cause death, all MI and any revascularisation that have been recommended by Academic Research Consortium (ARC) 18 after commencement of the LEADERS trial. We have also included individual endpoints including cardiac mortality and stent thrombosis at 5-year follow-up. An independent clinical events committee blindly adjudicated all events. Patient safety was assessed at prespecified intervals by an independent data and safety monitoring board. 
Statistical analysis
Continuous variables are presented as mean±SD, and categorical data as counts and percentages. Patients were analysed on an intention-to-treat analysis. Time-to-event variables are presented as Kaplan-Meier curves, and incidences compared using the log-rank test. All data were analysed using SAS V.9.3 (SAS Institute, Cary, North Carolina, USA).
RESULTS

Patient characteristics
Out of 1707 patients enrolled in the LEADERS trial, 573 patients were with AMI-298 with NSTEMI and 275 with STEMI. These patients were treated with either BES (n=280) or SES (n=293). Study flow chart is shown in figure 1 . Patients in the BES and SES groups were well-matched for baseline demographic, clinical and angiographic characteristics (table 1).
Procedural and medication details
A lesion-level comparison for angiographic and procedural parameters did not show any difference between the two treatment groups (table 2) . There was also no difference in use of evidencebased medication in the BES and SES groups, especially the use of antiplatelet therapy throughout the 5-year follow-up (table 3) . Dual antiplatelet therapy was mandated for 12 months postdevice implantation; however, only two-third of patients in each group were taking dual antiplatelet therapy at 1 year (BES 65.9% vs SES 59.9%, p=0.154). At 5 years, majority of patients in both groups were taking aspirin (93.6% vs 91%, p=0.280).
Clinical outcomes
All-cause mortality in the overall AMI population of LEADERS trial was 4.7% at 1-year follow up and 13.3% at 5-year follow-up (figure 2). Coronary intervention with a BES, compared with SES, significantly reduced POCE (28.9% vs 42.3%, relative risk (RR) 0.61, 95% CI 0.47 to 0.82, p=0.001) at 5-year follow-up (figure 2). Furthermore, MACE was also significantly lower in the BES group (18.2% vs 25.9%, RR 0.67, 95% CI 0.47 to 0.95, p=0.025) at 5-year follow-up (figure 3). However, there was no difference in individual endpoints of death, cardiac death, MI, target vessel revascularisation, target lesion revascularisation or stent thrombosis in the BES and SES groups ( figure 2 ). There was a trend towards reduction in the risk of definite (4.3% vs 6.8%, RR 0.61, 95% CI 0.30 to 1.25, p=0.174) and definite/probable (5.4% vs 8.5%, HR 0.61, 95% CI 0.32 to 1.16, p=0.128) stent thrombosis with BES compared with SES (figure 2). The incidence of stent thrombosis according to ARC-defined time periods of acute, subacute, late and very late is shown in table 4. This benefit of BES on stent thrombosis was seen at both short-term and long-term follow-up as evident by the landmark analysis (figure 4).
Stratified analysis according to AMI type
Dividing AMI population further into STEMI and NSTEMI groups also revealed similar baseline characteristics among the two treatment arms (see online supplementary table S1). Angiographic and procedural characteristics of STEMI and NSTEMI subgroups are shown in online supplementary table S2. Five-year outcomes stratified by STEMI and NSTEMI population revealed that coronary intervention with BES improved POCE compared with intervention with SES in both AMI groups (see online supplementary table S3). In the STEMI group, cardiac death and MACE were significantly lower in the BES group compared with SES group; however, there was no difference in the NSTEMI group (figure 3). Furthermore, there was a trend towards reduction in definite (3.7% vs 8.6%, RR 0.41, 95% CI 0.15 to 1.18, p=0.088) and definite/probable (4.4% vs 10.0%, RR 0.43, 95% CI 0.16 to 1.11, p=0.070) stent thrombosis with use of BES in STEMI population (see online supplementary table S3).
DISCUSSION
This post hoc analysis of patients with AMI in the LEADERS trial has shown improved 5-year clinical outcomes with coronary intervention using BES containing biodegradable polymer reducing POCE and MACE. Coronary intervention with a BES, compared with SES, was particularly beneficial in STEMI population, reducing POCE, MACE, cardiac death, repeat revascularisation and stent thrombosis.
The choice of stent in patients undergoing PCI for AMI has remained debatable. Coronary intervention with first-generation DES-eluting sirolimus or paclitaxel from a durable polymer has generally reduced need for revascularisation, but has shown no improvement in mortality compared with intervention with BMS. 6 19 20 Furthermore, risk of late stent thrombosis with firstgeneration DES tends to offset benefit from reduction in revascularisation in patients with STEMI as seen in real-world registries, 8 9 clinical trials 21 and a recent meta-analysis of 15 clinical trials comparing BMS and first-generation DES. 10 Newer-generation DES, eluting zotarolimus, everolimus or biolimus from biocompatible or biodegradable polymers, have been death, MI and target lesion revascularisation (11.9% vs 14.2%, p=0.19) at 1-year follow-up. 12 The COMFORTABLE-AMI (Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) trial, comparing BES against BMS, demonstrated the superiority of the biodegradable polymer BES to BMS with the identical metallic platform in terms of a significant reduction in the primary endpoint of MACE defined as the composite of cardiac death, target vessel-related MI and ischaemia-driven target lesion revascularisation (4.3% vs 8.7%, p=0.004) and POCE (8.4% vs 12.2%, p=0.04) at 1-year follow-up. 13 Definite stent thrombosis was numerically lower in the BES group (0.9% vs 2.1%, p=0.10), and there was no difference in mortality (2.9% vs 3.5%, p=0.53).
13 Two-year follow-up results were recently reported, showing persistent benefit of BES over BMS. 22 A pooled analysis of the EXAMINATION and COMFORTABLE-AMI trials also showed that newer-generation DES improve safety and efficacy compared with BMS at 1-year follow-up. 23 Further follow-up is awaited to evaluate the long-term impact of durable polymer newer-generation DES on very late stent thrombosis and its associated clinical impact.
Previous studies comparing zotarolimus-eluting and everolimus-eluting second-generation stents have not been able to show a convincing superiority over the first-generation DES in patients with AMI. ZEST-AMI compared the efficacy and safety of zotarolimus-eluting stents (n=108) against first-generation SES (n=110) and paclitaxel-eluting stents (n=110) in patients with STEMI. At 12 months, cumulative incidence rates of primary endpoint (MACE, composite of death, MI and ischaemia-driven target vessel revascularisation) in the zotarolimus-eluting, sirolimus-eluting and paclitaxel-eluting stents were 11.3%, 8.2% and 8.2%, respectively ( p=0.834).
15 XAMI (XienceV Stent vs. Cypher Stent in Primary PCI for Acute Myocardial Infarction) trial has compared everolimus-eluting stent against the firstgeneration SES and reported a lower rate of MACE (composite of cardiac death, AMI or any target vessel revascularisation) with everolimus-eluting stent (4.0% vs 7.7%, p=0.048) but no significant difference in cardiac mortality (1.5% vs 2.7%, p=0.36) or the incidence of definite/probable stent thrombosis (1.2% vs 2.7%, p=0.21) at 1 year.
14 However, at 3-year follow-up, there was no difference in everolimus-eluting stent and SES groups for MACE (everolimus-eluting stent 8.0% vs SES 10.5%, p=0.30), cardiac death (2.5% vs 2.7%, p=0.86) and definite/probable stent thrombosis (2.3% vs 3.2%, p=0.60). AMI substudies of other trials comparing everolimus-eluting stent against SES, including Basket-PROVE (the BASKET-Prospective Validation Examination), 24 EXCELLENT (Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting) 25 and SORT-OUT IV (The Scandinavian Organization for Randomized Trials with Clinical Outcome IV), 26 have also showed no significant advantage of everolimus-eluting stent over SES in patients with AMI or STEMI. Our study, for the first time, has shown that BES with biodegradable polymer, compared with the durable polymer SES, reduced cardiac death as well as stent thrombosis in STEMI population at 5-year follow-up.
The main strengths of the current study, compared with previous reports of newer-generation DES in AMI population, include having an 'all-comers' AMI population and the longest available (5-year) follow-up. Due to an 'all-comer' design, this study included patients with STEMI with complex anatomical disease (22% patients had multivessel disease, 38% patients had lesions >20 mm). This may explain a slightly higher incidence of adverse events in both arms of study compared with other reports. The sample size in this study is moderate; however, due to longer follow-up, we were able to demonstrate a beneficial effect of BES in reducing cardiac death, which was not evident at 1-year follow-up of the current study as well as in the COMFORTABLE-AMI trial. The long-term follow-up also provides additional insights into late stent thrombosis, which is largely blamed on durable polymer. 27 Undoubtedly, stent thrombosis is multifactorial in origin; patient-related, procedurerelated or device-related factors may play a role. 27 Our results indicate that patients with AMI remain at a significant risk of late stent thrombosis even in the BES group (incidence of late stent thrombosis in the BES group: non-AMI 0.3%, STEMI 1.6%, NSTEMI 3.0%). 28 Therefore, adhering to an evidencebased medical therapy, including antiplatelet drugs, is vital in these high-risk patients. Furthermore, the dual antiplatelet regimen in the LEADERS trial included aspirin and clopidogrel. Figure 4 Kaplan-Meier curves for stent thrombosis with landmark analysis. AMI, acute myocardial infarction; BES, biolimus-eluting stent; SES, sirolimus-eluting stent.
However, newer P2Y 12 inhibitors ( prasugrel and ticagrelor) with better clinical outcomes have largely replaced clopidogrel as part of dual antiplatelet therapy. 29 30 This study has several limitations. It is a post hoc analysis of the data, and results should be viewed with caution. Some baseline characteristics, including ischaemia time, door-to-balloon time and thrombectomy use, were unavailable in both of the studied groups. The trial was not powered for stent thrombosis in various subgroups; therefore, possibility of a type I statistical error cannot be excluded. Type I error was also not corrected for multiple comparison. However, stent thrombosis according to the definitions of ARC was a prespecified endpoint and was adjudicated by an independent clinical events committee, and the incidence of definite stent thrombosis continued to diverge between the two investigated devices up to 5 years, which would make the play of chance unlikely.
CONCLUSIONS
The newer-generation BES with biodegradable polymer compared with SES with durable polymer provided significant improvements in clinical outcomes in patients with AMI at 5-year follow-up. The benefit appeared more significant in the subgroup of patients with STEMI. Our results suggest that BES should be favourably considered for treating patients with STEMI. However, long-term follow-up of the COMFORTABLE-AMI trial and further larger studies are needed to confirm our findings.
Key messages
What is already known on this subject? Clinical trials have confirmed the efficacy of percutaneous coronary intervention (PCI) in the treatment of acute myocardial infarction. Use of stents has been shown to reduce major adverse cardiac events compared with balloon angioplasty alone. However, the choice of stent in patients undergoing PCI for acute myocardial infarction remains debatable.
What might this study add?
This study highlights that patients with acute myocardial infarction have shown improved 5-year clinical outcomes with biolimus-eluting stent (BES) containing biodegradable polymer reducing major cardiac adverse events (absolute risk reduction: 7.7%). Coronary intervention with a BES, compared with a sirolimus-eluting stent (SES), was particularly beneficial in ST-elevation myocardial infarction (STEMI) population.
How might this impact on clinical practice?
This study, for the first time, has shown that coronary intervention with a biodegradable polymer BES, compared with the durable polymer SES, reduced cardiac death as well as stent thrombosis in STEMI population at 5-year follow-up; hence, use of the newer generation biodegradable polymer BES should be recommended in patients with STEMI.
